¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high dose rate intraluminal radiotherapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® basal metabolic rate(BMR) ÇÑ±Û ±âÃÊ´ë»çÀ²
¼³¸í   
  Ç¥ÁØ ±âÃÊ´ë»ç·®°ú ºñ±³ÇßÀ» ¶§ °³Ã¼ ±âÃÊ´ë»ç·®ÀÌ º¸À̴ ÆíÂ÷¸¦ Ç¥½ÃÇϴ Áö¼ö. ±âÃÊ´ë»ç·®Àº »ý¸íÀ» À¯ÁöÇϴµ¥ ÇÊ¿äÇÑ ÃÖ¼ÒÇÑÀÇ ¿¡³ÊÁö ´ë»ç·®À̸ç, ¼º°ú ¿¬·ÉÀÌ µ¿ÀÏÇÑ °Ç°­ÀÎÀÇ ±âÃÊ´ë»ç·®Àº Ã¼Ç¥¸éÀû¿¡ ºñ·ÊÇÑ´Ù. À̰ÍÀ» Ã¼Ç¥¸éÀûÀÇ ¹ýÄ¢À̶ó°í Çϸç, 1882³â µ¶ÀÏÀÇ ´ë»ç»ý¸®ÇÐÀÚ M. ºê·ç³Ê¿¡ ÀÇÇØ Á¦Ã¢µÇ¾ú´Ù. Ã¼Ç¥¸éÀûÀº ½ÅÀå°ú Ã¼Áß¿¡ ÀÇÇØ »êÃâµÈ´Ù. µû¶ó¼­ ¼º-¿¬·É-½ÅÀå-üÁßÀ» ¾Ë¸é Ç¥ÁرâÃÊ·® Y°¡ »êÃâµÇ°í ½ÇÁ¦ÀÇ ±âÃÊ´ë»ç·® X´Â »ê¼Ò¼Òºñ·®°ú ÀÌ»êȭź¼Ò ¹ß»ý·®¿¡¼­ »êÃâµÈ´Ù. ±×¸®°í X¿Í YÀÇ Â÷À̸¦ Y·Î ³ª´« °ª(%)À» ±âÃÊ´ë»çÀ²À̶ó°í ÇÑ´Ù. °æÇèÀûÀ¸·Î ¾òÀº BMRÀÇ °£´ÜÇÑ ÃøÁ¤¹ýµµ ÀÖÀ¸¸ç ´ÙÀ½°ú °°Àº ½ÄÀ¸·Î ±¸ÇÑ´Ù. ÀÌ ½Ä¿¡¼­ ¸ÆÆøÀ̶õ ÃÖ°íÇ÷¾Ð°ú ÃÖÀúÇ÷¾ÐÀÇ Â÷¸¦ ¸»ÇÑ´Ù. BMR(%)=0.75(1ºÐ ¸Æ¹Ú¼ö + 0.74¡¿¸ÆÆø)£­72. BMRÀÌ 10% À̳»À̸é Á¤»ó¹üÀ§, +10% ÀÌ»óÀ̸頱âÃÊ´ë»çÇ×Áø, £­10% ÀÌÇÏÀ̸頱âÃÊ´ë»ç ÀúÇ϶ó°í ÇÑ´Ù. ±âÃÊ´ë»ç´Â °øº¹½Ã(½ÄÈÄ 10½Ã°£ °æ°ú)¿¡ ¾ÈÁ¤µÈ »óÅ¿¡¼­ ´ÜÀ§ ½Ã°£´ç ÀÌ¿ëµÇ´Â ¿¡³ÊÁöÀÇ ¾ç, Áï, ÇÑ ½Ã°£´ç, ¸ö Ç¥¸éÀÇ 1m2´ç ¶Ç´Â ¸ö¹«°Ô 1kg ´ç Ä®·Î¸®·Î ³ªÅ¸³½´Ù. À̰ÍÀº °³Àο¡ µû¶ó ´Ù¸£¸ç Àå±â°£¿¡´Â °ÅÀÇ º¯È­°¡ ¾øÁö¸¸ Áúº´ µîÀ¸·Î ÀÎÇØ º¯µ¿µÈ´Ù. ½ÇÃøÇÑ ±âÃÊ´ë»ç¸¦ Ç¥ÁØÄ¡¿Í ºñ±³ÇÔÀ¸·Î½á Áúº´ÀÇ Áø´Ü µî¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖ´Ù BMR=(½ÇÃøÄ¡-Ç¥ÁØÄ¡)/Ç¥ÁØÄ¡ ¡¿100(%)·Î ³ªÅ¸³½´Ù.
¿µ¹® radiation dose ÇÑ±Û ¹æ»ç¼±·®
¼³¸í   
  ¹æ»ç¼±Á¶»çÀÇ Á¤µµ. ¹æ»ç¼±»ý¹°ÇÐÀ̳ª ÀÎüÀÇ ¹æ»ç¼±¹æÈ£¿¡¼­´Â Àü¸®¹æ»ç¼±ÀÇ ¾ç, Áï ¼±·®ÀÌ ¹®Á¦°¡ µÈ´Ù. ¹æ»ç¼±·®¿¡¼­µµ ±¹Á¦´ÜÀ§°è(SI)°¡ Ã¤¿ëµÇ¾î ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)ÀÇ ±Ç°í¿¡ µû¶ó¼­ ´ÙÀ½ÀÇ ¿©·¯ ´ÜÀ§°¡ ³Î¸® »ç¿ëµÈ´Ù. ¨ç Èí¼ö¼±·®(absorbed dose). ¹°ÁúÀÇ ´ÜÀ§Áú·®ÀÌ ¹æ»ç¼±¿¡ ÀÇÇØ ¹Þ¾ÆµéÀ̴ ¿¡³ÊÁö. ÀÌ ´ÜÀ§´Â ¹æ»ç¼± ¹× ¹°ÁúÀÇ Á¾·ù°¡ ¾î¶°ÇÑ °ÍÀÌ´õ¶óµµ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±¹Á¦´ÜÀ§´Â J/kgÀ̸ç À̰Ϳ¡ °íÀ¯ÇÑ ¸íĪÀ¸·Î ±×·¹ÀÌ(gray, ±âÈ£ Gy)°¡ ºÎ¿©µÈ´Ù. 1Gy=100¶óµå(rad). ¨è Á¶»ç¼±·®(exposure) ¶Ç´Â °øÁß¼±·®. X¼± ¶Ç´Â ¥ã¼±¿¡ ÇÑÇØ¼­ »ç¿ëµÈ´Ù. ±¹Á¦´ÜÀ§´Â C/kg. ¨é ¼±·®´ç·®(dose equivalent). ¹æ»ç¼±¹æÈ£¸¦ À§ÇØ »ç¿ëµÇ´Â ¾ç. ±âÈ£´Â H. H´Â ¹æ»ç¼±ÀÇ Á¾·ù¿Í ¿¡³ÊÁö¿¡ ÀÇÇØ »ýü¿¡ Áִ ȿ°ú¸¦ º¸Á¤Çϴ ¼±Áú°è¼ö(Q)¿Í ±× ¹ÛÀÇ ÀÎÀÚ(¿¹¸¦ µé¸é ¼±·®·ü, ¹æ»ç¼ºµ¿À§¿ø¼Ò¿¡ ÀÇÇÑ ³»ºÎÇÇÆø½Ã¿¡´Â ±× ÇÙÁ¾ÀǠü³»ºÐÆ÷ µî)¿¡ ±Ù°ÅÇÑ º¸Á¤°è¼ö(N)¸¦ Èí¼ö¼±·®(D)¿¡ °öÇÑ °Í, Áï H=D-Q-N. ¶ÇÇÑ DÀÇ ´ÜÀ§¸¦ Gy ¶Ç´Â rad·Î Ç¥½ÃÇÏ¿´À» ¶§ HÀÇ ´ÜÀ§¸¦ °¢°¢ ½Ãº£¸£Æ®(sievert, ±âÈ£ Sv) ¹× ·½(rem)À̶ó°í ÇÑ´Ù. µû¶ó¼­ 1 Sv=102rem. ÀϹÝÀûÀ¸·Î ´ÜÀ§½Ã°£´çÀÇ ¼±·®À» ¼±·®·ü(dose rate)À̶ó°í ÇÑ´Ù.
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
¿µ¹® dose ÇÑ±Û ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
¼³¸í   
  1. ¾àÁ¦¸¦ ÇÑ ¹ø ¶Ç´Â ÇÏ·ç¿¡ »ç¿ëÇϰųª º¹¿ëÇϴ ºÐ·®. 2. ¹°ÁúÀ̳ª Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ÀÛ¿ë Á¤µµ¸¦ ³ªÅ¸³»´Â ¾ç. Áï, ¹æ»ç¼±·®À̶ó´Â °³³äÀº ¾î¶² ÇÑ Á¡¿¡ ÀÔ»çÇϴ ¹æ»ç¼±°ú ±× Á¡ ±Ùó¿¡ Àִ ¹°Áú¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀû È¿°ú¿ÍÀÇ °ü°Ô¸¦ Á¤·®ÀûÀ¸·Î ³ªÅ¸³»´Â °øÅëÀΠôµµ·Î¼­ »ý°¢µÈ °ÍÀÌ´Ù. ¶óµå(rad)·Î ³ªÅ¸³»´Â Èí¼ö·®, ·»Æ®°Õ(R)À¸·Î ³ªÅ¸³»´Â Á¶»ç ¼±·®, ·½(rem)À¸·Î ³ªÅ¸³»´Â ¼±·® ´ç·®À¸·Î ±¸ºÐÇÏ¿© ¾´´Ù.
¿µ¹® ESR(Erythrocyte Sedimentation Rate) ÇÑ±Û ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ
¼³¸í   
  Ç÷¾×ÀÌ ÀÀ°íµÇ´Â °ÍÀ» ¹æÁöÇϴ Ç×ÀÀ°íÁ¦¸¦ ³ÖÀº Ç÷¾×À» Ä§°­¿ë À¯¸®°ü¿¡ ³Ö¾î °¡¸¸È÷ ¼¼¿ö µÎ¾úÀ» ¶§ ÀûÇ÷±¸°¡ °¡¶ó¾É´Â ¼Óµµ¸¦ À̸£´Â ¸»ÀÌ´Ù. 1918³â ½º¿þµ§ÀÇ º´¸®ÇÐÀÚ ÆÄ·¹¿ì½ºÀǠâ¾È¿¡ ÀÇÇÑ °ÍÀÌ´Ù. ÃøÁ¤¹æ¹ýÀ¸·Î ¿©·¯ °¡Áö°¡ Àִµ¥, ±¹Á¦Ç¥ÁعýÀ¸·Î´Â 1973³â ¿þ½ºÅͱ׷»¹ýÀÇ 1½Ã°£¹ýÀÌ ¼±Á¤µÇ¾úÀ¸¸ç, 1977³â ±×°ÍÀ» °³Á¤ÇÏ¿© °¢±¹¿¡¼­ ¾²µµ·Ï ±ÇÀåÇϰí ÀÖ´Ù. 1½Ã°£ ÈĠħ°­¿ë À¯¸®°ü À§ÂÊÀÇ Ç÷Àå±âµÕÀÇ ³ôÀ̸¦ mm·Î Àоî, ±×°ÍÀ» ÀûÇ÷±¸Ä§°­ÀÇ 1½Ã°£°ªÀ¸·Î ÇÑ´Ù. ¸¸¾à Ç÷Àå°ú ÀûÇ÷±¸ÀÇ °æ°è°¡ ¼±¸íÇÏÁö ¸øÇÑ °æ¿ì, ÀûÇ÷±¸ÀÇ ¹Ðµµ°¡ ±× ÀÌÇÏ¿¡¼­´Â ÀÏÁ¤ÇÏ´Ù°í ¿©°ÜÁö´Â °÷ÀÇ ´«±ÝÀ» Àоî ÀûÇ÷±¸Ä§°­ÀÇ 1½Ã°£°ªÀ¸·Î ÇÑ´Ù. ÃøÁ¤ ¶§ÀÇ ½Ç³»¿Âµµ´Â 18~25µµ·Î ÇÑ´Ù. ÀϹÝÀûÀ¸·Î À̺¸´Ù ¿Âµµ°¡ ³ôÀº °æ¿ì´Â Ç÷ħ¹ÝÀÀÀÌ ÃËÁøµÇ¸ç, ³·Àº °æ¿ì´Â ´Ê¾îÁø´Ù. Á¤»ó °ªÀº 2~10mm(³²ÀÚ), 3~15mm(¿©ÀÚ)À̸ç 15¼¼ ÀÌÇÏÀÇ ¾î¸°ÀÌ, 50¼¼ ÀÌ»óÀÇ °í·ÉÀÚ¿¡¼­´Â ¾à°£ ³ô´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate
    °í¼±·®·ü
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • intraluminal brachytherapy
    °ü³»±ÙÁ¢Ä¡·á
  • intraluminal fluid
    °ü³»¾×, °­³»¾×, °ø°£³»¾×
  • intraluminal scan
    °ü³»½ºÄµ
  • continuous hyperfractionated accelerated radiotherapy
    ¿¬¼Ó°úºÐÇÒ°¡¼Ó¹æ»ç¼±Ä¡·á
  • endoluminal radiotherapy
    °ü³»¹æ»ç¼±Ä¡·á
  • hyperfractionated radiotherapy
    °ú´ÙºÐÇÒ¹æ»ç¼±Ä¡·á
  • inverse radiotherapy
    µµÄ¡¹æ»ç¼±Ä¡·á
  • mantle radiotherapy
    ¸ÇƲ¹æ»ç¼±Ä¡·á
  • radiotherapy
    ¹æ»ç¼±Ä¡·á, ¹æ»ç¼±¿ä¹ý
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • dose rate
    1. ¼±·®·ü 2. Åõ¿©·®
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high-dose
    °í¿ë·®
  • radiotherapy
    ¹æ»ç¼±Ä¡·á
  • high altitude
    °íÁö-, °í¼Ò-
  • high risk group
    °íÀ§Ç豺
  • high density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹é
  • high grade squamous intraepithelial lesion
    °íµî±ÞÆíÆò»óÇdz»º´ÅÍ
  • high potency
    °íÈ¿´É, °í¿ª°¡, °íÀáÀç·Â
  • high resolution computed tomography
    °íÇØ»óÀü»ê´ÜÃþÃÔ¿µ¼ú
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • average dose
    Æò±Õ¿ë·®, Æò±Õ¼±·®
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • lethal dose
    Ä¡»ç·®
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®À²°ü³»¹æ»ç¼±Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate
    °í¼±·®·ü
  • high-dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • intraluminal brachytherapy
    °ü³»±ÙÁ¢Ä¡·á
  • intraluminal fluid
    °ü³»¾×, °­³»¾×, °ø°£³»¾×
  • intraluminal scan
    °ü³»½ºÄµ
  • continuous hyperfractionated accelerated radiotherapy
    ¿¬¼Ó°úºÐÇÒ°¡¼Ó¹æ»ç¼±Ä¡·á
  • endoluminal radiotherapy
    °ü³»¹æ»ç¼±Ä¡·á
  • hyperfractionated radiotherapy
    °ú´ÙºÐÇÒ¹æ»ç¼±Ä¡·á
  • inverse radiotherapy
    µµÄ¡¹æ»ç¼±Ä¡·á
  • mantle radiotherapy
    ¸ÇƲ¹æ»ç¼±Ä¡·á
  • radiotherapy
    ¹æ»ç¼±Ä¡·á
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate
    °í¼±·®À²
  • radiotherapy
    ¹æ»ç¼± Ä¡·á
  • radiotherapy
    ¹æ»ç¼±Ä¡·á
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • high dose tolerance
    °ú·®°ü¿ë
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • high dose rate
    °í¼±·®À²
  • intraluminal brachytherapy
    °ü³»±ÙÁ¢Ä¡·á
  • intraluminal fluid
    °­³»¾×(Ë·Ò®äû).
  • intraluminal scan
    °ü³» ½ºÄµ
  • intraluminal scan
    °ü°­³» (η˷Ү)ÀÇ ½ºÄµ
  • endoluminal radiotherapy
    °ü³» ¹æ»ç¼± Ä¡·á
  • inverse radiotherapy
    µµÄ¡ ¹æ»ç¼± Ä¡·á
  • mantle radiotherapy
    ¸ÇƲ¹æ»ç¼±Ä¡·á
  • radiotherapy
    ¹æ»ç¼±Ä¡·á
  • radiotherapy
    ¹æ»ç¼± Ä¡·á
  • high dose tolerance
    °ú·®°ü¿ë
  • cardiac rate =heart rate
    ½É¹Ú¼ö(¡­â¦).
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • continuous low dose rate irradiation
    Àú¼±·®À²¿¬¼Ó¹æ»ç¼±Á¶»ç
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • egg negative conversion rate
    Ãæ¶õÀ½ÀüÀ²
  • egg reduction rate
    Ãæ¶õ°¨¼ÒÀ²
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • radiotherapy
    ¹æ»ç¼±Ä¡·á (Û¯ÞÒàÊö½Öû)
  • basal metabolic rate
    "±â(ÃÊ,º»)´ë»çÀ²(Ðñ(õ¨,Üâ)ÓÛÞóëÒ)"
  • catalytic rate constant
    Ã˸żӵµ»ó¼ö(õºØÚáÜÓøßÈâ¦)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • growth rate constant
    ¼ºÀå¼Óµµ »ó¼ö (à÷íþáÜÓøßÈâ¦)
  • rate
    À²(ëÒ)
  • rate constant
    ¼Óµµ»ó¼ö(áÜÓøßÈâ¦)
  • rate-determining step
    ¼Óµµ°áÁ¤ ´Ü°è(áÜÓøÌ½ïÒÓ«Í­)
  • rate equation
    ¼Óµµ ¹æÁ¤½Ä(áÜÓøÛ°ïïãÒ)
  • rate-limiting step
    ¼ÓµµÁ¦ÇÑ ´Ü°è(áÜÓøð¤ùÚÓ«Í­)
  • rate zonal centrifugation
    ¼Óµµ ±¸¿ª ¿ø½ÉºÐ¸®(áÜÓøÏ¡æ´êÀãýÝÂ×î)
  • mutation rate
    º¯ÀÌÀ²(ܨì¶ëÒ)
  • reaction rate
    ¹ÝÀÀ ¼Óµµ·Ð(ÚãëëáÜÓøÖå)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific rate constant
    ƯÀÌ ¼Óµµ»ó¼ö(÷åì¶áÜÓøßÈâ¦)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intraluminal scan
    °ü³»½ºÄµ
  • dose rate
    ¼±·®·ü
  • intraoperative radiotherapy
    ¼ö¼úÁß¹æ»ç¼±Ä¡·á
  • radiotherapy
    ¹æ»ç¼±¿ä¹ý, ¹æ»ç¼±Ä¡·á
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • compression rate
    ¾ÐÃàÀ²
  • erythrocyte sedimentation rate
    ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ¼Óµµ
  • frame rate
    È­¸éÀ²
  • metabolic rate
    ´ë»çÀ²
  • molecular tumbling rate
    ºÐÀÚÅÒºí¸µÀ²
  • pulse rate
    ¸Æ¹Ú¼ö, ÆÞ½ºÀ²
  • pulse repetition rate
    ÆÞ½º¹Ýº¹À²
  • rate
    ¼Óµµ, ¾ç, À², ºñ
  • relaxation rate
    ÀÌ¿ÏÀ²
  • respiration rate
    È£Èí·ü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
TD tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IL Intraluminal
HDR High Dose Rate
LDR Low Dose Rate
PDR Pulse-Dose-Rate
CLDR continuous low dose rate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • intraoperative radiotherapy
    ¼ö¼ú Áß ¹æ»ç¼± Ä¡·á
  • radiotherapy
    ¹æ»ç¼± ¿ä¹ý, ¹æ»ç¼± Ä¡·á
    1. Àü¸® ¹æ»ç¼±À» ÀÌ¿ëÇÏ¿© Áúº´À» Ä¡·áÇÏ´Â ¹æ¹ý. 2. Á¾·¡¿¡´Â X¼± ¿ä¹ý ¹× ¶óµã ¿ä¹ýÀ» ¸»ÇÑ °ÍÀ̾úÀ¸³ª ÃÖ±Ù¿¡ ¿Í¼­ Ãʰí¾Ð ¹æ»ç¼±, Áß¼ºÀÚ¼±, Àΰø ¹æ»ç¼º µ¿À§¿ø¼Ò µîÀ» Æ÷ÇÔÇÏ´Â ¹æ»ç¼± Ä¡·á¸¦ ÀÏÄ´ ¸». Àû´çÇÑ ¾çÀÇ ¹æ»ç¼±À» ȯºÎ¿¡ Á¶»çÇÔÀ¸·Î½á º´¼Ò¸¦ Ä¡·áÇÏ´Â ¹æ¹ýÀÌ´Ù. X¼±À̳ª ¶óµãÀÇ ¥ã¼± µîÀÇ ¹æ»ç¼±À» ¾ÏÁ¾À̳ª À°Á¾ µî¿¡ Á¶»çÇÏ¸é ¸Å¿ì À¯È¿ÇÏ´Ù´Â »ç½ÇÀº ±× ¹ß°ß Á÷ÈÄ¿¡ ÀÌ¹Ì ÀÎÁ¤µÇ¾úÀ¸³ª ½ÇÁ¦·Î ¾ÏÀ» Ä¡·áÇÏ¿© ³´°Ô ÇÑ »ç·ÊµéÀº 1920³â´ëºÎÅÍÀ̰í, ±× µ¿¾È ¿©·¯ °¡Áö·Î ¿¬±¸ º¸¿ÏµÇ¾î ¿À´Ã¿¡ À̸£°í ÀÖ´Ù. ¹æ»ç¼± ¿ä¹ýÀ¸·Î ÀÌ¿ëµÇ´Â °ÍÀº ÀÌ¿ÂÈ­ ¹æ»ç¼±À¸·Î, X¼±À̳ª ¥ã¼±°ú °°Àº ÀüÀÚ±âÆÄ¿Í ¥á¼±, ¥â¼±, Áß¼ºÀÚ¼±¤ý¾ç¼ºÀÚ¼±°ú °°Àº ÀÔÀÚ¼±ÀÌ´Ù. ÀÌµé ¹æ»ç¼±Àº »ýü¿¡ ´ëÇØ ÆÄ±« ÀÛ¿ëÀÌ ÀÖ°í, ¾î´À Á¤µµ ÀÌ»óÀ» ÇÇÆø½ÃŰ¸é ¼¼Æ÷°¡ »ç¸ê ºØ±«µÇ¾î ¹ö¸°´Ù. ±×¿Í °°Àº Á÷Á¢ÀûÀÎ ÆÄ±« ÀÛ¿ëÀ» ÀÌ¿ëÇÏ¿© ¾Ï µîÀÇ Á¶Á÷À» ¼¶¸ê½ÃÄÑ Ä¡·á ¸ñÀûÀ» ÀÌ·ç´Â °ÍÀ¸·Î, ¾ÏÁ¾À̳ª À°Á¾ À̿ܿ¡µµ Ç÷°üÁ¾À̳ª ÄÉ·ÎÀ̵å¿Í °°Àº ¾ç¼º Á¾¾çÀ» ºñ·ÔÇÏ¿© ¿©·¯ °¡Áö ÇǺκ´¿¡µµ ÀÀ¿ëµÈ´Ù. ¶ÇÇÑ °£Á¢Àû ÀÛ¿ë¿¡ ÀÇÇÑ °ÍÀ¸·Î´Â ½Å°æ¿¡ ÀÛ¿ëÇÏ¿© ±â´ÉÀû ¾ïÁ¦¸¦ ÃÊ·¡ÇÏ´Â °æ¿ì³ª ÆÄ±« ÀÛ¿ë¿¡ ÀÇÇØ »ý±ä ´Ü¹é ºÐÇØ »ê¹° µî¿¡ ÀÇÇÑ °£Á¢ÀûÀÎ ÀÚ±Ø ÀÛ¿ë¿¡ ÀÇÇÑ °Íµµ ÀÖ´Ù. °áÇÙÀ̳ª õ½Ä µî¿¡ ´ëÇÑ °ÍÀÌ ±× ´ëÇ¥ÀûÀÎ ¿¹·Î, È­ÇÐ ¿ä¹ý¸¸À¸·Î ³­Ä¡ÀÎ °æ¿ì¿¡ ¹Ì·®ÀÇ ¹æ»ç¼±À» Á¶»çÇϸé ȯºÎ¿¡ ºÐÇØ »ê¹°ÀÌ »ý±â°í, ±¹¼ÒÀûÀÎ ÀÚ±Ø ÀÛ¿ë¿¡ ÀÇÇØ ±Þ¼Óµµ·Î °üÇØµÈ´Ù. 1895³â ·ÛÆ®°ÕÀÇ X¼± ¹ß°ß°ú 98³â Äû¸®¿¡ ÀÇÇÑ ¶óµã ¹ß°ß ÀÌÈÄ ¹Ý¼¼±â µ¿¾È ±× Áß ¶óµãÀÌ ¹æ»ç¼± Ä¡·áÀÇ ÁÖ¿ªÀ» ¸Ã¾Æ ¿Ô´Ù. ÃÊâ±â¿¡´Â Ä¡·á¿¡ »ç¿ëµÇ´Â X¼± ¼±·®À» ¸ô¶ó °¢ÀÚÀÇ °æÇè¿¡ ÀÇÇØ ¹è·®ÇÏ¿´À¸¸ç, ¿¹±âÄ¡ ¸øÇÑ X¼± È­»óÀ» ¾ß±âÇÏ´Â Àϵµ ÀÖ¾ú´Ù. ½ÃÀÏÀÌ °æ°úÇÔ¿¡ µû¶ó ½Åü Ç¥¸éÀ¸·ÎºÎÅÍ ½ÉºÎ¿¡ À§Ä¡ÇÏ´Â Á¾¾ç¿¡ ´Ù·®ÀÇ X¼±À» µµ´Þ½Ã۱â À§ÇØ X¼± ¹ß»ý ÀåÄ¡ÀÇ °³·®ÀÌ ½ÃµµµÇ¾î 1920~30³â´ë´Â ºü¸¥ ¹ßÀüÀ» ÀÌ·èÇÏ¿´´Ù. ¶óµãÀº ½º½º·Î ¹æÃâÇÏ´Â ¥ã¼±ÀÇ °­µµ¿Í ¼±ÁúÀÌ ¿©·¯ ¾Ï ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ ÀÌ»óÀûÀ̾ Áö³­ ¹Ý¼¼±â»Ó¸¸ ¾Æ´Ï¶ó ÇöÀçµµ ¾Ï Ä¡·á¿¡ Å« ¸òÀ» ´ã´çÇϰí ÀÖ´Ù. 1934³â P. Äû¸®, ·Î·»½º, Æä¸£¹Ì µîÀÌ °¢°¢ ¥á ÀÔÀÚ, Áß¼ºÀÚ, »çÀÌŬ·ÎÆ®·Ð µîÀ» ÀÌ¿ëÇÏ¿© óÀ½À¸·Î Àΰø ¹æ»ç¼º µ¿À§¿ø¼ÒÀÇ »ý»ê¿¡ ¼º°øÇÏ¿´°í, ÀÌ¾î Æä¸£¹Ì´Â 39³â ´º¿å¿¡ óÀ½À¸·Î ¿øÀڷθ¦ °Ç¼³ÇÔÀ¸·Î½á Á¦2Â÷´ëÀü ÈÄ ¿À´Ã³¯¿¡ º¸´Â °¢Á¾ Àΰø ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ ´ë·® »ý»êÇÒ ¼ö ÀÖ´Â ±æÀ» Åͳõ¾Ò´Ù. Áï, ¶óµã À̿ܿ¡µµ ´Ù·®ÀÇ ¥ã¼±À» ³¾ ¼ö ÀÖ´Â ¹°ÁúÀ» ´Ù°¢µµ·Î ¸ð»öÇÑ °á°ú¿´´Ù. À̵é Àΰø ¹æ»ç¼º µ¿À§¿ø¼Ò´Â X¼±°ú ¶óµãÀÇ ´ë¿ëÀº ¹°·Ð ³»¿ë µî ÀüÇô »õ·Î¿î ¾Ï Ä¡·áÀÇ ±æÀ» ¿­¾î ³õ¾ÒÀ¸¸ç, ±× ´ëÇ¥ÀûÀÎ ¿¹·Î¼­ ÄÚ¹ßÆ® 60 0CoÀ» ²ÅÀ» ¼ö ÀÖ´Ù. ÇöÀç ÀÌ¿ëµÇ°í ÀÖ´Â ¹æ»ç¼± ¿ä¹ý¿¡´Â ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù. ¨ç X¼± ½ÉºÎ Ä¡·á : 20¸¸ V Á¤µµÀÇ X¼±Ä¡·á°¡ ÁÖÀ̸ç, Ç¥À缺ÀÎ Áúȯ¿¡´Â 3¸¸~7¸¸ VÀÇ ¿¬¼±µµ ÀÌ¿ëµÈ´Ù. ¨è ¶óµã ¿ä¹ý : ´ë°³´Â ¥ã ¼± ¿ä¹ýÀ¸·Î ¹é±Ý°ü ¶Ç´Â ħÀÌ »ç¿ëµÇ¸ç, ÀÚ±ÃÀ̳ª ºñ°­ °°Àº ºÎÀ§¿¡´Â ü°­ ³» Á¶»ç¿Í ¶óµã ħ¿¡ ÀÇÇÑ Á¶Á÷³» Á¶»çµµ À¯È¿ÇÏ´Ù. ¨é ÄÚ¹ßÆ® 60ÀÇ ´ë·® Á¶»ç : 0Co¿¡¼­ ¹æÃâµÇ´Â ¥ã¼±ÀÇ ³ôÀº Åõ°ú·ÂÀº ÇǺο¡ Å« ¼Õ»óÀ» ÁÖÁö ¾Ê°í ÃæºÐÇÑ ¾çÀÇ ¹æ»ç¼±À» Á¾¾ç¿¡ ÂÚ ¼ö ÀÖÀ¸¹Ç·Î, Á¾·¡ X¼± Ä¡·á¿¡¼­ º¸´ø ½ÉÇÑ È­»ó¿¡ µû¸¥ °íÅëÀ» ÁÖÁö ¾Ê°í Ä¡·á°¡ °¡´ÉÇÑ µ¿½Ã¿¡ ÀÏ·üÀûÀÎ ±ÕµîÇÑ Åõ°ú·ÂÀ» °¡Áø´Ù. µû¶ó¼­ X¼± Ä¡·á¿¡¼­ ÈçÈ÷ °æÇèÇÑ ¹Ù¿Í °°ÀÌ °ñ°Ý Á¶Á÷¿¡ ¿©ºÐÀ¸·Î Èí¼öµÇ¾î Ä¡·á ÈÄ X¼± °ú´Ù Èí¼ö·Î ÀÎÇØ ¿¹±âÄ¡ ¸øÇÑ º´Àû °ñÀýÀÇ ¿ì·Áµµ ¾ø°Ô µÇ¾ú´Ù. »Ó¸¸ ¾Æ´Ï¶ó 0CoÀ¸·ÎºÎÅÍ ¹æÃâµÇ´Â ¹æ»ç¼±·®Àº ¼Õ½±°Ô °è»êÇÒ ¼ö ÀÖÀ¸¹Ç·Î °ú¼Ò, °ú´Ù Á¶¸í µî ±â¼ú»ó Âø¿ÀÀÇ ¿ì·Á°¡ ¾øÀ¸¸ç, ½Ã¼³, ÀåÄ¡ µîÀÌ ¸Å¿ì °£ÆíÇÏ¿© ÁøÀÚ, ȸÀü Á¶»ç¹ý µî Ä¡·á ±â¼úÀ» ÀÚÀ¯ÀÚÀç·Î ¹ßÈÖÇÒ ¼ö ÀÖ´Ù. Çѱ¹¿¡ 0CoÀÌ Ã³À½ µµÀÔ, °¡µ¿µÈ °ÍÀº 1963³â Çö ¿øÀڷº´¿ø¿¡ ÀÖ´Â 3,000 Ci ¿ë·®ÀÇ °ÍÀÌ´Ù. ÇÑÆí, º¸´Ù °­·ÂÇÑ X¼±À» »©³» ¾²±â À§ÇØ ¼³°èµÈ °ÍÀÌ ¼±Çü °¡¼Ó ÀåÄ¡·Î¼­ ¼º´É¸é¿¡¼­ º¸´Ù °³¼±µÈ °ÍÀÌ ¸¶ÀÌÅ©·ÎÆ®·ÐÀÌ´Ù. ¨ê Ãʰí¾Ð ¹æ»ç¼± ¿ä¹ý : 400¸¸~800¸¸ VÀÇ X¼±À» ³»´Â ¼±Çü °¡¼ÓÀåÄ¡
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • high repitition rate
    °í¹Ýº¹À², ³ôÀº ¹Ýº¹À²
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose rate variation
    ¼±·®·ü º¯È­
  • admixed high-copper alloy
    È¥ÇÕÇü °íµ¿ÇÕ±Ý
    °íµ¿ÇÕ±ÝÀÇ °¡Àå ¿À·¡µÈ ÇüÅ·μ­ Àº, ÁÖ¼®, 6% ÀÌÇÏÀÇ ±¸¸®¸¦ ÇÔÀ¯ÇÑ Àç·¡Çü Àúµ¿ÇԱݰú ´ë°Ô ±¸¸®°¡ ¸¹Àº Àº-±¸¸® °øÁ¤ ÇÕ±ÝÀÇ µÎ °¡Áö ºÐ¸»À» È¥ÇÕÇÏ¿© ±¸¸®ÀÇ ÃÑ·®À» Áõ°¡½ÃŲ °ÍÀÌ´Ù. Àúµ¿ Àç·¡Çü ÇÕ±ÝÀº Àý»èÇüÀÌ¸ç °íµ¿ÇÕ±ÝÀº ±¸»óÇüÀ̾ °á°úÀûÀ¸·Î Àý»èÇü°ú ±¸»óÇüÀÌ È¥ÇÕµÈ °ÍÀÌ´Ù.
  • high arched
    ³ôÀº ±¸°³±Ã
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high condylectomy
    °í °úµÎ ÀýÁ¦¼ú, »ó°úµÎ ÀýÁ¦¼ú
    »ó,ÇÏ¾Ç °úµÎÀÇ ÀϺκи¸À» ¿Ü°úÀûÀ¸·Î Á¦°ÅÇÏ´Â °Í.
  • high copper amalgam
    °íµ¿ ¾Æ¸»°¨
    ¾Æ¸»°¨ Çձݿ¡¼­ ±¸¸®ÀÇ ºñ°¡ ³ôÀº °Í.
  • high electron density
    °íÀüÀÚ ¹Ðµµ
    ÀüÀÚµéÀÇ ¹Ðµµ°¡ ³ôÀº °÷.
  • high energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÎ»ê °áÇÕ ÇüŰ¡ ³ôÀº ¿¡³ÊÁö·Î ÀÌ·ç¾îÁø »óÅÂ. ÀÌ °áÇÕÀº ¾Æ³×³ë½Å »ïÀλê. Æ÷½ºÆ÷Å©·¹¾ÆÆ¾. ´ç ´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high energy radiation
    °í¿¡³ÊÁö ¹æ»ç¼±
    ³ôÀº ¿¡³ÊÁöÀÇ ¹æ»ç¼±À» ¹æÃâÇÏ´Â °Í.
  • high fever
    °í¿­
    ³ôÀº ¿­.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
radiotherapy, high-energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; X-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
(12 Dec 1998)
intraluminal Within any tube.
Synonym: intraluminal.
(05 Mar 2000)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
radiotherapy <oncology> The treatment of disease by ionising radiation.
Origin: Gr. Therapeia = cure
(18 Nov 1997)
radiotherapy, adjuvant Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
(12 Dec 1998)
radiotherapy, computer-assisted Computer systems or programs used in accurate computations for providing radiation dosage treatment to patients.
(12 Dec 1998)
radiotherapy dosage The total amount of radiation absorbed by tissues as a result of radiotherapy.
(12 Dec 1998)
radiotherapy localization Planning the size and alignment of radiation beams to encompass the neoplasm to be treated.
(05 Mar 2000)
radiotherapy planning, computer-assisted Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
(12 Dec 1998)
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • radiotherapy
    ¹æ»ç¼± Ä¡·á¹ý
  • radiotherapy
    ¹æ»ç¼± ¿ä¹ý;¹æ»ç¼± Ä¡·á»çÀÇ ÀÏ;-pist ¹æ»ç¼± Ä¡·á»ç
  • dose
    ¾àÀÇ 1ȸºÐ;~¿¡ Åõ¾àÇÏ´Ù;º¹¿ë½ÃŰ´Ù
  • maximum dose
    (¾àÀÇ) ±Ø·®
  • minimum dose
    ÃÖ¼Ò Åõ¾à·®
  • at any rate
    ÇÏ¿©Æ°
  • heart rate
    ¸Æ¹Ú
  • monthly rate
    1°³¿ù ¿ä±Ý
  • rate
    ºñÀ²,À²,(º¹¼ö)¿ä±Ý,Æò°¡ÇÏ´Ù
  • ad rate
    ±¤°í·á
  • bank rate
    ¾îÀ½ÇÒÀÎÀ²;ÀºÇàÀϺ¯
  • birth rate
    Ãâ»êÀ²
  • call rate
    ÄÝ·ÐÀÇ ÀÌÀ²
  • card rate
    Ç¥ÁظÅü¿ä±Ý(½Å¹®»ç.¹æ¼Û±¹ µîÀÌ °øÇ¥ÇÑ ±¤°í Ç¥ÁØ ¿ä±ÝÇ¥)
  • carload rate
    È­Â÷ Àü¼¼ Ãë±Þ ¿îÀÓ·ü
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á